Up a level |
Clark, Richard E ORCID: 0000-0002-1261-3299, Polydoros, Fotios ORCID: 0000-0001-5181-6817, Apperley, Jane F, Milojkovic, Dragana, Pocock, Christopher, Smith, Graeme, Byrne, Jenny L, de lavallade, Hugues, O'Brien, Stephen G, Coffey, Tony et al (show 2 more authors)
(2017)
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
The Lancet Haematology, 4 (7).
E310-E316.
Copland, Mhairi, Slade, Daniel, McIlroy, Graham, Horne, Gillian, Byrne, Jenny L, Rothwell, Kate, Brock, Kristian, De Lavallade, Hugues, Craddock, Charles, Clark, Richard E ORCID: 0000-0002-1261-3299 et al (show 5 more authors)
(2022)
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
LANCET HAEMATOLOGY, 9 (2).
E121-E132.